CF-Carvacrol

• Description:

  CF-Carvacrol is an orally active lipid-lowering agent synthesized by merging the pharmacophores of Carvacrol (HY-N0711) and Clofibric acid (HY-B1415) . CF-Carvacrol has a good affinity for PPAR-α. CF-Carvacrol has significant hypolipidemic activity and may exert antioxidant and anti-inflammatory activity by activating the Nrf2/HO-1 signaling pathway to reduce liver injury. CF-Carvacrol can be used for the study of CF-induced liver damage[1].

• UNSPSC:

  12352005

• Target:

  Interleukin Related; Keap1-Nrf2; PPAR

• Related Pathways:

  Cell Cycle/DNA Damage; Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB; Vitamin D Related/Nuclear Receptor

• Applications:

  Metabolism-sugar/lipid metabolism

• Field of Research:

  Metabolic Disease; Inflammation/Immunology

• Smiles:

  CC(C1=CC(OC(C(C)(OC2=CC=C(C=C2)Cl)C)=O)=C(C=C1)C)C

• Molecular Formula:

  C20H23ClO3

• Molecular Weight:

  346.85

• References & Citations:

  [1]Shi X, et al. Optimization of clofibrate by carvacrol results in a new hypolipidemic compound with low hepatic injury. Bioorg Med Chem Lett. 2025 May 1;120:130116./

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported